In:
Transfusion, Wiley, Vol. 62, No. 7 ( 2022-07), p. 1321-1333
Abstract:
A national serosurvey of U.S. blood donors conducted in partnership with the Centers for Disease Control and Prevention (CDC) was initiated to estimate the prevalence of SARS‐CoV‐2 infections and vaccinations. Methods Beginning in July 2020, the Nationwide Blood Donor Seroprevalence Study collaborated with multiple blood collection organizations, testing labs, and leadership from government partners to capture, test, and analyze approximately 150,000 blood donation specimens per month in a repeated, cross‐sectional seroprevalence survey. Results A CDC website ( https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence ) provided stratified, population‐level results to public health professionals and the general public. Discussion The study adapted operations as the pandemic evolved, changing specimen flow and testing algorithms, and collecting additional data elements in response to changing policies on universal blood donation screening and administration of SARS‐CoV‐2 spike‐based vaccines. The national serosurvey demonstrated the utility of serosurveillance testing of residual blood donations and highlighted the role of the blood collection industry in public–private partnerships during a public health emergency.
Type of Medium:
Online Resource
ISSN:
0041-1132
,
1537-2995
Language:
English
Publisher:
Wiley
Publication Date:
2022
detail.hit.zdb_id:
2018415-3
